Ursachen der chronischen Nierenschädigung in Patienten mit Lebererkrankungen – Pathophysiologie und Therapiemöglichkeiten

Zusammenfassung

Eine akute oder chronische Nierenschädigung bei gleichzeitig bestehender Lebererkrankung stellt ein häufiges Problem dar und geht im weiteren klinischen Verlauf mit zahlreichen Komplikationen sowie einer gesteigerten Dialysepflichtigkeit und Mortalität einher.

Die Prävalenz einer chronischen Niereninsuffizienz (CNI) bei Patienten mit Lebererkrankungen ist hoch, nicht zuletzt wegen parallel bestehender Komorbiditäten (z. B. metabolisches Syndrom, chronische Entzündungsprozesse, Hyperkoagulabilität, Hyperfibrinolyse, Diabetes mellitus, Dyslipidämie usw.). Doch nicht jede chronische Verschlechterung der Nierenretentionsparameter lässt sich auf ein hepatorenales Syndrom zurückführen. Neben diesem sind die häufigsten Ursachen der CNI bei bestehenden Lebererkrankungen die diabetische Nephropathie, die alkoholassoziierte IgA-Nephropathie, die mit Hepatitis C assoziierte membranoproliferative Glomerulonephritis und die mit Hepatitis B assoziierte membranöse Glomerulonephritis.

Koexistente Erkrankungen, ähnlich bzw. parallel ablaufende pathophysiologische Mechanismen und überlappende Erscheinungsbilder stellen hinsichtlich der Ursachenfindung und entsprechenden Behandlung der CNI im Rahmen einer existenten Lebererkrankung eine Herausforderung an den Kliniker dar. Diese Übersichtsarbeit skizziert sowohl häufige als auch seltene Entitäten, die zu einer chronischen Nierenschädigung in diesem speziellen Patientenkollektiv führen, und zeigt einen Überblick zu therapeutischen Möglichkeiten.

Abstract

Acute and chronic kidney disease concurs commonly with liver disease and is associated with a wide array of complications including dialysis dependency and increased mortality. Patients with liver disease or liver cirrhosis show a higher prevalence of chronic kidney disease. This is attributed to concomitant comorbidities, such as metabolic syndrome, chronic inflammation, hypercoagulability, hyperfibrinolysis, diabetes mellitus and dyslipidaemias. But chronic progressive kidney disease is not always due to hepatorenal syndrome. Beyond that, other diseases or disease entities should be considered. Among them are diabetic nephropathy, secondary IgA nephropathy, hepatitis C -associated membranoproliferative Glomerulonephritis (MPGN) and hepatitis B-associated membranous nephropathy.

Coexisting diseases, similar underlying pathophysiologic mechanisms, or simultaneously concurring pathophysiological processes and overlapping clinical manifestations, impede the etiologic diagnosis and corresponding treatment of chronic kidney disease in the setting of chronic liver disease. In this review, we focus on common and rare pathologies, which can lead to chronic kidney disease in this particular patient group and try to summarize the most recent therapeutic modalities.

Schlüsselwörter

Leberinsuffizienz - Leberzirrhose - Nierenschädigung - chronische Niereninsuffizienz - hepatorenales Syndrom - HRS - Hepatitis B - Hepatitis C - Diabetes mellitus - Pathophysiologie - Nierenbiopsie

Key words

liver insufficiency - liver cirrhosis - kidney injury - chronic renal insufficiency - hepatorenal syndrome - HRS - hepatitis B - hepatitis C - diabetes mellitus - pathophysiology - kidney biopsy

Publication History

Received: 21 January 2021

Accepted: 24 February 2021

Article published online:
16 March 2021

• Literatur

• 1 Slack A, Yeoman A, Wendon J. Renal Dysfunction in Chronic Liver Disease. New York, NY: Springer New York; 2010: 349-364
• 2 Targher G, Chonchol MB, Byrne CD. CKD and nonalcoholic fatty liver disease. Am J Kidney Dis 2014; 64: 638-652
• 3 Bonora E, Targher G. Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol 2012; 9: 372-381
• 4 Lum EL, Homkrailas P, Bunnapradist S. Evaluation of Renal Disease in Patients With Cirrhosis. J Clin Gastroenterol 2020; 54: 314-321
• 5 Arase Y, Suzuki F, Kobayashi M. et al The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease. Intern Med 2011; 50: 1081-1087
• 6 Targher G, Mantovani A, Pichiri I. et al Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes. Diabetes Care 2014; 37: 1729-1736
• 7 Wong F, Reddy KR, O'Leary JG. et al Impact of Chronic Kidney Disease on Outcomes in Cirrhosis. Liver Transpl 2019; 25: 870-880
• 8 Velez JCQ, Therapondos G, Juncos LA. Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis. Nat Rev Nephrol 2020; 16: 137-155
• 9 Mazzolini G, Sowa JP, Atorrasagasti C. et al Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence. Cells 2020; 9
• 10 Stefan N. [New aspects of nonalcoholic steatohepatitis]. Internist (Berl) 2019; 60: 128-132
• 11 Adams LA, Anstee QM, Tilg H. et al Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017; 66: 1138-1153
• 12 Tolman KG, Fonseca V, Dalpiaz A. et al Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007; 30: 734-743
• 13 Wlazlo N, Beijers HJ, Schoon EJ. et al High prevalence of diabetes mellitus in patients with liver cirrhosis. Diabet Med 2010; 27: 1308-1311
• 14 Grancini V, Trombetta M, Lunati ME. et al Contribution of beta-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease. J Hepatol 2015; 63: 1484-1490
• 15 Targher G, Bertolini L, Rodella S. et al Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol 2010; 5: 2166-2171
• 16 Greco AV, Mingrone G, Mari A. et al Mechanisms of hyperinsulinaemia in Child's disease grade B liver cirrhosis investigated in free living conditions. Gut 2002; 51: 870-875
• 17 Shanik MH, Xu Y, Skrha J. et al Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse?. Diabetes Care 2008; 31 (Suppl. 02) S262-S268
• 18 Saitoh M. [Studies on histopathology of pancreas in portal hypertension]. Nihon Shokakibyo Gakkai Zasshi 1984; 81: 1444-1452
• 19 Gariani K, Philippe J, Jornayvaz FR. Non-alcoholic fatty liver disease and insulin resistance: from bench to bedside. Diabetes Metab 2013; 39: 16-26
• 20 Lecube A, Hernandez C, Genesca J. et al Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: A case-control study. Diabetes Care 2006; 29: 1096-1101
• 21 Bose SK, Shrivastava S, Meyer K. et al Hepatitis C virus activates the mTOR/S6K1 signaling pathway in inhibiting IRS-1 function for insulin resistance. J Virol 2012; 86: 6315-6322
• 22 Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705
• 23 Balaban YH, Korkusuz P, Simsek H. et al Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann Hepatol 2007; 6: 242-250
• 24 Itou M, Kawaguchi T, Taniguchi E. et al Dipeptidyl peptidase-4: a key player in chronic liver disease. World J Gastroenterol 2013; 19: 2298-2306
• 25 Yagmur E, Tacke F, Weiss C. et al Elevation of Nepsilon-(carboxymethyl)lysine-modified advanced glycation end products in chronic liver disease is an indicator of liver cirrhosis. Clin Biochem 2006; 39: 39-45
• 26 Sebekova K, Kupcova V, Schinzel R. et al Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis – amelioration by liver transplantation. J Hepatol 2002; 36: 66-71
• 27 Vlassara H, Uribarri J. Advanced glycation end products (AGE) and diabetes: cause, effect, or both?. Curr Diab Rep 2014; 14: 453
• 28 Christen V, Treves S, Duong FH. et al Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A. Hepatology 2007; 46: 558-565
• 29 Orsi E, Grancini V, Menini S. et al Hepatogenous diabetes: Is it time to separate it from type 2 diabetes?. Liver Int 2017; 37: 950-962
• 30 Rahier J, Loozen S, Goebbels RM. et al The haemochromatotic human pancreas: a quantitative immunohistochemical and ultrastructural study. Diabetologia 1987; 30: 5-12
• 31 Tang SC. Diabetic nephropathy: a global and growing threat. Hong Kong Med J 2010; 16: 244-245
• 32 Espinel E, Agraz I, Ibernon M. et al Renal Biopsy in Type 2 Diabetic Patients. J Clin Med 2015; 4: 998-1009
• 33 Krolewski AS. Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes. Diabetes Care 2015; 38: 954-962
• 34 Imano E, Nishida T, Shibata M. et al Significance of oral glucose tolerance test for the diagnosis of diabetes mellitus in patients with liver cirrhosis. Intern Med 1999; 38: 918
• 35 Lahousen T, Hegenbarth K, Ille R. et al Determination of glycated hemoglobin in patients with advanced liver disease. World J Gastroenterol 2004; 10: 2284-2286
• 36 Nishida T, Tsuji S, Tsujii M. et al Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. Am J Gastroenterol 2006; 101: 70-75
• 37 Nishida T. Diagnosis and Clinical Implications of Diabetes in Liver Cirrhosis: A Focus on the Oral Glucose Tolerance Test. J Endocr Soc 2017; 1: 886-896
• 38 Ranjbar G, Mikhailidis DP, Sahebkar A. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!. Metabolism 2019; 101: 154001
• 39 Tacelli M, Celsa C, Magro B. et al Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?. Pharmaceuticals (Basel) 2018; 11
• 40 Peter PR, Lupsa BC. Personalized Management of Type 2 Diabetes. Curr Diab Rep 2019; 19: 115
• 41 Schubert M, Hansen S, Leefmann J. et al Repurposing Antidiabetic Drugs for Cardiovascular Disease. Front Physiol 2020; 11: 568632
• 42 Sumida Y, Yoneda M, Tokushige K. et al Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. Int J Mol Sci 2020; 21
• 43 Grancini V, Resi V, Palmieri E. et al Management of diabetes mellitus in patients undergoing liver transplantation. Pharmacol Res 2019; 141: 556-573
• 44 Kumar R. Hepatogenous Diabetes: An Underestimated Problem of Liver Cirrhosis. Indian J Endocrinol Metab 2018; 22: 552-559
• 45 Heerspink HJL, Stefansson BV, Correa-Rotter R. et al Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020; 383: 1436-1446
• 46 McMurray JJV, Docherty KF, Jhund PS. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. Reply. N Engl J Med 2020; 382: 973
• 47 Packer M, Anker SD, Butler J. et al Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020; 383: 1413-1424
• 48 Perkovic V, Jardine MJ, Neal B. et al Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380: 2295-2306
• 49 Wiviott SD, Raz I, Bonaca MP. et al Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019; 380: 347-357
• 50 Bakris G, Oshima M, Mahaffey KW. et al Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m(2): Subgroup Analysis of the Randomized CREDENCE Trial. Clin J Am Soc Nephrol 2020; 15: 1705-1714
• 51 Chalasani N, Younossi Z, Lavine JE. et al The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328-357
• 52 Estes C, Anstee QM, Arias-Loste MT. et al Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol 2018; 69: 896-904
• 53 Musso G, Gambino R, Tabibian JH. et al Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 2014; 11: e1001680
• 54 European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 2016; 59: 1121-1140
• 55 Non-alcoholic Fatty Liver Disease Study G, Lonardo A, Bellentani S et al. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis 2015; 47: 997-1006
• 56 Younossi Z, Anstee QM, Marietti M. et al Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018; 15: 11-20
• 57 Kendrick J, Chonchol MB. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol 2008; 4: 672-681
• 58 Kronenberg F. Emerging risk factors and markers of chronic kidney disease progression. Nat Rev Nephrol 2009; 5: 677-689
• 59 Targher G, Chonchol M, Miele L. et al Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost 2009; 35: 277-287
• 60 Targher G, Byrne CD. Diagnosis and management of nonalcoholic fatty liver disease and its hemostatic/thrombotic and vascular complications. Semin Thromb Hemost 2013; 39: 214-228
• 61 Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol 2020; 72: 785-801
• 62 Musso G, Cassader M, Cohney S. et al Emerging Liver-Kidney Interactions in Nonalcoholic Fatty Liver Disease. Trends Mol Med 2015; 21: 645-662
• 63 Lanaspa MA, Cicerchi C, Garcia G. et al Counteracting roles of AMP deaminase and AMP kinase in the development of fatty liver. PLoS One 2012; 7: e48801
• 64 Lanaspa MA, Sanchez-Lozada LG, Choi YJ. et al Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. J Biol Chem 2012; 287: 40732-40744
• 65 Sanchez-Lozada LG, Andres-Hernando A, Garcia-Arroyo FE. et al Uric acid activates aldose reductase and the polyol pathway for endogenous fructose and fat production causing development of fatty liver in rats. J Biol Chem 2019; 294: 4272-4281
• 66 Anstee QM, Seth D, Day CP. Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease. Gastroenterology 2016; 150: 1728-1744 e1727
• 67 Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol 2018; 68: 268-279
• 68 Oniki K, Saruwatari J, Izuka T. et al Influence of the PNPLA3 rs738409 Polymorphism on Non-Alcoholic Fatty Liver Disease and Renal Function among Normal Weight Subjects. PLoS One 2015; 10: e0132640
• 69 Musso G, Cassader M, Gambino R. PNPLA3 rs738409 and TM6SF2 rs58542926 gene variants affect renal disease and function in nonalcoholic fatty liver disease. Hepatology 2015; 62: 658-659
• 70 Mantovani A, Zusi C, Sani E. et al Association between PNPLA3rs738409 polymorphism decreased kidney function in postmenopausal type 2 diabetic women with or without non-alcoholic fatty liver disease. Diabetes Metab 2019; 45: 480-487
• 71 Sun DQ, Zheng KI, Xu G. et al PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels. Liver Int 2020; 40: 107-119
• 72 Targher G, Mantovani A, Alisi A. et al Relationship Between PNPLA3 rs738409 Polymorphism and Decreased Kidney Function in Children With NAFLD. Hepatology 2019; 70: 142-153
• 73 Marzuillo P, Di Sessa A, Guarino S. et al Nonalcoholic fatty liver disease and eGFR levels could be linked by the PNPLA3 I148M polymorphism in children with obesity. Pediatr Obes 2019; 14: e12539
• 74 Shen B, Lu LG. Efficacy and safety of drugs for nonalcoholic steatohepatitis. J Dig Dis 2021;
• 75 Vilar-Gomez E, Calzadilla-Bertot L, Friedman SL. et al Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2017; 45: 332-344
• 76 Saha MK, Julian BA, Novak J. et al Secondary IgA nephropathy. Kidney Int 2018; 94: 674-681
• 77 Seikrit C, Rauen T, Floege J. [Immunoglobulin A nephropathy]. Internist (Berl) 2019; 60: 432-439
• 78 Axelsen RA, Crawford DH, Endre ZH. et al Renal glomerular lesions in unselected patients with cirrhosis undergoing orthotopic liver transplantation. Pathology 1995; 27: 237-246
• 79 McGuire BM, Julian BA, Bynon Jr JS. et al Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann Intern Med 2006; 144: 735-741
• 80 Calmus Y, Conti F, Cluzel P. et al Prospective assessment of renal histopathological lesions in patients with end-stage liver disease: effects on long-term renal function after liver transplantation. J Hepatol 2012; 57: 572-576
• 81 Hommos MS, El-Zoghby ZM. Renal Outcomes in Patients With IgA Nephropathy Undergoing Liver Transplant: A Retrospective Cohort Study. Transplant Direct 2017; 3: e193
• 82 Suzuki H, Kiryluk K, Novak J. et al The pathophysiology of IgA nephropathy. J Am Soc Nephrol 2011; 22: 1795-1803
• 83 Tissandie E, Morelle W, Berthelot L. et al Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89-IgA and IgG-IgA complexes: common mechanisms for distinct diseases. Kidney Int 2011; 80: 1352-1363
• 84 Scurt FG, Bose K, Canbay A. et al [Paradigm shift in understanding Acute kidney injury in patients with chronic liver disease: From pathophysiology to defining disease entities]. Z Gastroenterol 2020; 58: 254-266
• 85 Francoz C, Durand F, Kahn JA. et al Hepatorenal Syndrome. Clin J Am Soc Nephrol 2019; 14: 774-781
• 86 Singhal J, Sharma J. IgA nephropathy secondary to liver disease. Pediatr Nephrol 2018; 33: 2393
• 87 Deviere J, Content J, Denys C. et al Immunoglobulin A and interleukin 6 form a positive secretory feedback loop: a study of normal subjects and alcoholic cirrhotics. Gastroenterology 1992; 103: 1296-1301
• 88 Pouria S, Barratt J. Secondary IgA nephropathy. Semin Nephrol 2008; 28: 27-37
• 89 Rauen T, Eitner F, Fitzner C. et al Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. N Engl J Med 2015; 373: 2225-2236
• 90 Liu LJ, Yang YZ, Shi SF. et al Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial. Am J Kidney Dis 2019; 74: 15-22
• 91 Floege J, Feehally J. Treatment of IgA nephropathy and Henoch-Schonlein nephritis. Nat Rev Nephrol 2013; 9: 320-327
• 92 Frisch G, Lin J, Rosenstock J. et al Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant 2005; 20: 2139-2145
• 93 Lafayette RA, Canetta PA, Rovin BH. et al A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction. J Am Soc Nephrol 2017; 28: 1306-1313
• 94 Pozzi C, Andrulli S, Pani A. et al Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol 2010; 21: 1783-1790
• 95 Sarcina C, Tinelli C, Ferrario F. et al Changes in Proteinuria and Side Effects of Corticosteroids Alone or in Combination with Azathioprine at Different Stages of IgA Nephropathy. Clin J Am Soc Nephrol 2016; 11: 973-981
• 96 Lv J, Zhang H, Wong MG. et al Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. JAMA 2017; 318: 432-442
• 97 Pozzi C. Pro: STOP immunosuppression in IgA nephropathy?. Nephrol Dial Transplant 2016; 31: 1766-1770
• 98 Tesar V, Troyanov S, Bellur S. et al Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study. J Am Soc Nephrol 2015; 26: 2248-2258
• 99 Pozzi C, Andrulli S, Del Vecchio L. et al Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004; 15: 157-163
• 100 Manno C, Torres DD, Rossini M. et al Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 2009; 24: 3694-3701
• 101 Smerud HK, Barany P, Lindstrom K. et al New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria. Nephrol Dial Transplant 2011; 26: 3237-3242
• 102 Fellstrom BC, Barratt J, Cook H. et al Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet 2017; 389: 2117-2127
• 103 Ismail G, Obrisca B, Jurubita R. et al Budesonide versus systemic corticosteroids in IgA Nephropathy: A retrospective, propensity-matched comparison. Medicine (Baltimore) 2020; 99: e21000
• 104 Vierling JM, Kerkar N, Czaja AJ. et al Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta-Analyses Supporting AASLD Guidelines. Hepatology 2020;
• 105 Doycheva I, Watt KD, Gulamhusein AF. Autoimmune hepatitis: Current and future therapeutic options. Liver Int 2019; 39: 1002-1013
• 106 Sallustio F, Curci C, Di Leo V. et al A New Vision of IgA Nephropathy: The Missing Link. Int J Mol Sci 2019; 21
• 107 Bhimma R, Coovadia HM. Hepatitis B virus-associated nephropathy. Am J Nephrol 2004; 24: 198-211
• 108 Kupin WL. Viral-Associated GN: Hepatitis B and Other Viral Infections. Clin J Am Soc Nephrol 2017; 12: 1529-1533
• 109 Pipili CL, Papatheodoridis GV, Cholongitas EC. Treatment of hepatitis B in patients with chronic kidney disease. Kidney Int 2013; 84: 880-885
• 110 Johnson RJ, Couser WG. Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. Kidney Int 1990; 37: 663-676
• 111 Lai KN, Li PK, Lui SF. et al Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 1991; 324: 1457-1463
• 112 Li P, Wei RB, Tang L. et al Clinical and pathological analysis of hepatitis B virus-related membranous nephropathy and idiopathic membranous nephropathy. Clin Nephrol 2012; 78: 456-464
• 113 Fervenza FC, Sethi S, Specks U. Idiopathic membranous nephropathy: diagnosis and treatment. Clin J Am Soc Nephrol 2008; 3: 905-919
• 114 He XY, Fang LJ, Zhang YE. et al In situ hybridization of hepatitis B DNA in hepatitis B-associated glomerulonephritis. Pediatr Nephrol 1998; 12: 117-120
• 115 Xie Q, Li Y, Xue J. et al Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy. Am J Nephrol 2015; 41: 345-353
• 116 Lin CY. Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon. Kidney Int 1995; 47: 225-230
• 117 Yang Y, Ma YP, Chen DP. et al A Meta-Analysis of Antiviral Therapy for Hepatitis B Virus-Associated Membranous Nephropathy. PLoS One 2016; 11: e0160437
• 118 Mahajan V, D'Cruz S, Nada R. et al Successful Use of Entecavir in Hepatitis B-associated Membranous Nephropathy. J Trop Pediatr 2018; 64: 249-252
• 119 Jung WJ, Jang JY, Park WY. et al Effect of tenofovir on renal function in patients with chronic hepatitis B. Medicine (Baltimore) 2018; 97: e9756
• 120 De Clercq E. Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections. Biochem Pharmacol 2018; 153: 2-11
• 121 Berchtold L, Zanetta G, Dahan K. et al Efficacy and Safety of Rituximab in Hepatitis B Virus-Associated PLA2R-Positive Membranous Nephropathy. Kidney Int Rep 2018; 3: 486-491
• 122 Buonomo AR, Viceconte G, Scotto R. et al Seronegative occult HBV reactivation complicated with fulminant acute liver failure after rituximab for chronic inflammatory demyelinating polyneuropathy. Infect Dis (Lond) 2020; 52: 216-218
• 123 Chang WY, Chiu YC, Chiu FW. et al High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing Chemotherapy. J Infect Dis 2020; 222: 1345-1352
• 124 Venkataseshan VS, Lieberman K, Kim DU. et al Hepatitis-B-associated glomerulonephritis: pathology, pathogenesis, and clinical course. Medicine (Baltimore) 1990; 69: 200-216
• 125 Sharma A, Sharma K. Hepatotropic viral infection associated systemic vasculitides-hepatitis B virus associated polyarteritis nodosa and hepatitis C virus associated cryoglobulinemic vasculitis. J Clin Exp Hepatol 2013; 3: 204-212
• 126 Mucino-Bermejo MJ. Mechanisms of kidney dysfunction in the cirrhotic patient: Non-hepatorenal acute-on-chronic kidney damage considerations. Ann Hepatol 2020; 19: 145-152
• 127 Hughes LB, Bridges Jr SL. Polyarteritis nodosa and microscopic polyangiitis: etiologic and diagnostic considerations. Curr Rheumatol Rep 2002; 4: 75-82
• 128 Pagnoux C, Seror R, Henegar C. et al Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum 2010; 62: 616-626
• 129 Guillevin L, Mahr A, Callard P. et al Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 2005; 84: 313-322
• 130 Guillevin L, Mahr A, Cohen P. et al Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa. Arthritis Rheum 2004; 51: 482-487
• 131 de Luna G, Chauveau D, Aniort J. et al Plasma exchanges for the treatment of severe systemic necrotizing vasculitides in clinical daily practice: Data from the French Vasculitis Study Group. J Autoimmun 2015; 65: 49-55
• 132 Fernanda F, Serena C, Giustina R. et al Mycophenolate mofetil treatment in two children with severe polyarteritis nodosa refractory to immunosuppressant drugs. Rheumatol Int 2012; 32: 2215-2219
• 133 Castillo I, Martinez-Ara J, Olea T. et al High prevalence of occult hepatitis C virus infection in patients with primary and secondary glomerular nephropathies. Kidney Int 2014; 86: 619-624
• 134 Sabry AA, Sobh MA, Irving WL. et al A comprehensive study of the association between hepatitis C virus and glomerulopathy. Nephrol Dial Transplant 2002; 17: 239-245
• 135 Kupin WL. Viral-Associated GN: Hepatitis C and HIV. Clin J Am Soc Nephrol 2017; 12: 1337-1342
• 136 Barsoum RS, William EA, Khalil SS. Hepatitis C and kidney disease: A narrative review. J Adv Res 2017; 8: 113-130
• 137 Bunchorntavakul C, Mitrani R, Reddy KR. Advances in HCV and Cryoglobulinemic Vasculitis in the Era of DAAs: Are We at the End of the Road?. J Clin Exp Hepatol 2018; 8: 81-94
• 138 Terrier B, Carrat F, Krastinova E. et al Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis: data from 242 cases included in the CryoVas survey. Ann Rheum Dis 2013; 72: 374-380
• 139 Fogo AB, Lusco MA, Najafian B. et al AJKD Atlas of Renal Pathology: Cryoglobulinemic Glomerulonephritis. Am J Kidney Dis 2016; 67: e5-e7
• 140 Harle JR, Disdier P, Dussol B. et al Membranoproliferative glomerulonephritis and hepatitis C infection. Lancet 1993; 341: 904
• 141 Johnson RJ, Gretch DR, Yamabe H. et al Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328: 465-470
• 142 Gragnani L, Visentini M, Fognani E. et al Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology 2016; 64: 1473-1482
• 143 Saadoun D, Thibault V, Si Ahmed SN. et al Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis 2016; 75: 1777-1782
• 144 Sise ME, Bloom AK, Wisocky J. et al Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology 2016; 63: 408-417
• 145 Bonacci M, Lens S, Londono MC. et al Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus-Associated Cryoglobulinemia Treated With Direct-Acting Antivirals. Clin Gastroenterol Hepatol 2017; 15: 575-583 e571
• 146 Obata F, Murakami T, Miyagi J. et al A case of rapid amelioration of hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis treated by interferon-free directly acting antivirals for HCV in the absence of immunosuppressant. CEN Case Rep 2017; 6: 55-60
• 147 Tsuge M, Hiramatsu A, Shinohara F. et al Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report. Hepatol Res 2016; 46: 944-948
• 148 Gane E, Lawitz E, Pugatch D. et al Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. N Engl J Med 2017; 377: 1448-1455
• 149 Bruchfeld A, Roth D, Martin P. et al Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol 2017; 2: 585-594
• 150 Alric L, Ollivier-Hourmand I, Berard E. et al Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective. Kidney Int 2018; 94: 206-213
• 151 Toyoda H, Kumada T, Tada T. et al Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis. J Gastroenterol 2016; 51: 741-747
• 152 Kawakami Y, Imamura M, Ikeda H. et al Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study. J Viral Hepat 2016; 23: 850-856
• 153 De Vita S, Quartuccio L, Isola M. et al A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64: 843-853
• 154 Koratala A, Zeng X. Rituximab therapy for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis. Clin Case Rep 2018; 6: 442-443
• 155 Montero N, Fava A, Rodriguez E. et al Treatment for hepatitis C virus-associated mixed cryoglobulinaemia. Cochrane Database Syst Rev 2018; 5: CD011403
• 156 Noble J, Jouve T, Malvezzi P. et al Renal complications of liver diseases. Expert Rev Gastroenterol Hepatol 2018; 12: 1135-1142
• 157 Mazzaro C, Dal Maso L, Quartuccio L. et al Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia without renal involvement: a multicentre open-label study. Clin Exp Rheumatol 2018; 36 (Suppl. 111) 107-114
• 158 Emery JS, Kuczynski M, La D. et al Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia. Am J Gastroenterol 2017; 112: 1298-1308
• 159 Dammacco F, Lauletta G, Russi S. et al Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis. Clin Exp Med 2019; 19: 1-21
• 160 Ozkok A, Yildiz A. Hepatitis C virus associated glomerulopathies. World J Gastroenterol 2014; 20: 7544-7554
• 161 Appel GB. Immune-complex glomerulonephritis – deposits plus interest. N Engl J Med 1993; 328: 505-506
• 162 Sansonno D, Lauletta G, Montrone M. et al Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture microdissection. Clin Exp Immunol 2005; 140: 498-506
• 163 Spatola L, Generali E, Angelini C. et al HCV-negative mixed cryoglobulinemia and kidney involvement: in-depth review on physiopathological and histological bases. Clin Exp Med 2018; 18: 465-471
• 164 Saadoun D, Terrier B, Semoun O. et al Hepatitis C virus-associated polyarteritis nodosa. Arthritis Care Res (Hoboken) 2011; 63: 427-435
• 165 Ramos-Casals M, Munoz S, Medina F. et al Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). J Rheumatol 2009; 36: 1442-1448
• 166 Angeletti A, Cantarelli C, Cravedi P. HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents. Front Med (Lausanne) 2019; 6: 20
• 167 Lai TS, Lee MH, Yang HI. et al Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study. Hepatology 2017; 66: 784-793
• 168 Sabry A, A EA, Sheashaa H et al. HCV associated glomerulopathy in Egyptian patients: clinicopathological analysis. Virology 2005; 334: 10-16
• 169 Pol S, Parlati L, Jadoul M. Hepatitis C virus and the kidney. Nat Rev Nephrol 2019; 15: 73-86
• 170 Fabrizi F, Messa P. Treatment Choices for Hepatitis C in Patients with Kidney Disease. Clin J Am Soc Nephrol 2018; 13: 793-795
• 171 Perico N, Cattaneo D, Bikbov B. et al Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol 2009; 4: 207-220
• 172 European Association for theStudy of the Liver. Electronic address eee, Clinical Practice Guidelines Panel C, representative EGB et al. EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol 2020; 73: 1170-1218
• 173 Sarrazin C, Zimmermann T, Berg T. et al [Prophylaxis, diagnosis and therapy of hepatitis-C-virus (HCV) infection: the German guidelines on the management of HCV infection – AWMF-Register-No.: 021/012]. Z Gastroenterol 2018; 56: 756-838
• 174 Jadoul M, Berenguer MC, Doss W. et al Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management. Kidney Int 2018; 94: 663-673
• 175 AASLD–IDSA. HCV guidance: recommendations for testing, managing, and treating hepatitis C. In; 2017: HCV Guidelines
• 176 Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009; 361: 1279-1290
• 177 Durand F, Graupera I, Gines P. et al Pathogenesis of Hepatorenal Syndrome: Implications for Therapy. Am J Kidney Dis 2016; 67: 318-328
• 178 Wong F. The evolving concept of acute kidney injury in patients with cirrhosis. Nat Rev Gastroenterol Hepatol 2015; 12: 711-719
• 179 Salerno F, Gerbes A, Gines P. et al Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 1310-1318
• 180 Gerbes AL, Labenz J, Appenrodt B. et al [Updated S2k-Guideline “Complications of liver cirrhosis”. German Society of Gastroenterology (DGVS)]. Z Gastroenterol 2019; 57: e168
• 181 Sort P, Navasa M, Arroyo V. et al Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. The New England journal of medicine 1999; 341: 403-409
• 182 Follo A, Llovet JM, Navasa M. et al Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994; 20: 1495-1501
• 183 Fasolato S, Angeli P, Dallagnese L. et al Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology 2007; 45: 223-229
• 184 Terra C, Guevara M, Torre A. et al Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology 2005; 129: 1944-1953
• 185 Gines A, Fernandez-Esparrach G, Monescillo A. et al Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111: 1002-1010
• 186 Angeli P, Fasolato S, Mazza E. et al Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial. Gut 2010; 59: 98-104
• 187 Akriviadis E, Botla R, Briggs W. et al Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-1648
• 188 Leithead JA, Ferguson JW, Bates CM. et al The systemic inflammatory response syndrome is predictive of renal dysfunction in patients with non-paracetamol-induced acute liver failure. Gut 2009; 58: 443-449
• 189 Lima C, Macedo E. Urinary Biochemistry in the Diagnosis of Acute Kidney Injury. Dis Markers 2018; 2018: 4907024
• 190 Davenport A, Argawal B, Wright G. et al Can non-invasive measurements aid clinical assessment of volume in patients with cirrhosis?. World J Hepatol 2013; 5: 433-438
• 191 Ostermann M, Joannidis M. Acute kidney injury 2016: diagnosis and diagnostic workup. Crit Care 2016; 20: 299
• 192 Francoz C, Nadim MK, Durand F. Kidney biomarkers in cirrhosis. J Hepatol 2016; 65: 809-824
• 193 Sinclair M, Gow PJ, Grossmann M. et al Review article: sarcopenia in cirrhosis – aetiology, implications and potential therapeutic interventions. Alimentary pharmacology & therapeutics 2016; 43: 765-777
• 194 Piano S, Rosi S, Maresio G. et al Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. Journal of hepatology 2013; 59: 482-489
• 195 Wong F, O'Leary JG, Reddy KR. et al New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology 2013; 145: 1280-1288 e1281
• 196 Belcher JM, Garcia-Tsao G, Sanyal AJ. et al Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology 2013; 57: 753-762
• 197 Fagundes C, Barreto R, Guevara M. et al A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. J Hepatol 2013; 59: 474-481
• 198 Tsien CD, Rabie R, Wong F. Acute kidney injury in decompensated cirrhosis. Gut 2013; 62: 131-137
• 199 de Carvalho JR, Villela-Nogueira CA, Luiz RR. et al Acute kidney injury network criteria as a predictor of hospital mortality in cirrhotic patients with ascites. Journal of clinical gastroenterology 2012; 46: e21-e26
• 200 Angeli P, Gines P, Wong F. et al Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Journal of hepatology 2015; 62: 968-974
• 201 Angeli P, Garcia-Tsao G, Nadim MK. et al News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol 2019; 71: 811-822
• 202 [Anonym]. Summary of Recommendation Statements. Kidney international supplements 2012; 2: 8-12
• 203 Simonetto DA, Gines P, Kamath PS. Hepatorenal syndrome: pathophysiology, diagnosis, and management. BMJ 2020; 370: m2687
• 204 Badr KF, Ichikawa I. Prerenal failure: a deleterious shift from renal compensation to decompensation. N Engl J Med 1988; 319: 623-629
• 205 Sansoe G, Silvano S, Mengozzi G. et al Loss of tubuloglomerular feedback in decompensated liver cirrhosis: physiopathological implications. Dig Dis Sci 2005; 50: 955-963
• 206 Stadlbauer V, Wright GA, Banaji M. et al Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology 2008; 134: 111-119
• 207 Bonavia A, Vece G, Karamchandani K. Prerenal acute kidney injury-still a relevant term in modern clinical practice?. Nephrol Dial Transplant 2020;
• 208 Ala A, Walker AP, Ashkan K. et al Wilson's disease. Lancet 2007; 369: 397-408
• 209 Scheiber IF, Bruha R, Dusek P. Pathogenesis of Wilson disease. Handb Clin Neurol 2017; 142: 43-55
• 210 Tsuchiya M, Takaki R, Kobayashi F. et al Multiple pseudofractures due to Fanconi's syndrome associated with Wilson's disease. Rinsho Shinkeigaku 2017; 57: 527-530
• 211 Wang H, Zhou Z, Hu J. et al Renal impairment in different phenotypes of Wilson disease. Neurol Sci 2015; 36: 2111-2115
• 212 Efe C, Ozaslan E, Purnak T. et al Membranous glomerulonephritis associated with autoimmune hepatitis and primary biliary cirrhosis overlap syndrome: a very rare condition. Eur J Gastroenterol Hepatol 2010; 22: 1149-1150
• 213 Fickert P, Krones E, Pollheimer MJ. et al Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice. Hepatology 2013; 58: 2056-2069
• 214 van Slambrouck CM, Salem F, Meehan SM. et al Bile cast nephropathy is a common pathologic finding for kidney injury associated with severe liver dysfunction. Kidney Int 2013; 84: 192-197
• 215 Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008; 48: 2064-2077
• 216 Russ KB, Stevens TM, Singal AK. Acute Kidney Injury in Patients with Cirrhosis. J Clin Transl Hepatol 2015; 3: 195-204
• 217 Hara N, Kawaguchi M, Takeda K. et al Retroperitoneal disorders associated with IgG4-related autoimmune pancreatitis. World J Gastroenterol 2014; 20: 16550-16558
• 218 Lei WH, Xin J, Shao CX. et al IgG4-related Kidney Disease Mimicking Malignant Ureter Tumor: Case Report and Literature Review. Medicine (Baltimore) 2016; 95: e2550
• 219 Esprit DH, Koratala A, Chornyy V. et al Obstructive Nephropathy Without Hydronephrosis: Suspicion Is the Key. Urology 2017; 101: e9-e10